Wo067ydlsdcdy9zifq5f diacarta

DiaCarta, Inc.

Richmond, CA, US

Headquartered in Richmond, California with an ISO 13485-certified facility, DiaCarta develops, manufactures and markets cancer research and IVD products for precision molecular diagnostics. We specialize in genomic testing for biomarkers and offer clinical sample testing services in our CLIA-certified lab. We have also established our business operations and clinical service lab in Shanghai and Nanjing, China, respectively. QClamp® and OptiSeq™ are xeno nucleic acid (XNA) based technologies that enable highly sensitive detection of actionable mutations using qPCR and next-generation sequencing (NGS) platforms, respectively, for liquid biopsy and other traditionally challenging specimens. Other XNA applications include CRISPR/Cas9 gene-editing event screening and adapter dimer removal for NGS library preparation.

Recent Publications

  • W. Yan, A. Zhang, M. Powell. Genetic Alteration and Mutation Profiling of... Show more »

Headquartered in Richmond, California with an ISO 13485-certified facility, DiaCarta develops, manufactures and markets cancer research and IVD products for precision molecular diagnostics. We specialize in genomic testing for biomarkers and offer clinical sample testing services in our CLIA-certified lab. We have also established our business operations and clinical service lab in Shanghai and Nanjing, China, respectively. QClamp® and OptiSeq™ are xeno nucleic acid (XNA) based technologies that enable highly sensitive detection of actionable mutations using qPCR and next-generation sequencing (NGS) platforms, respectively, for liquid biopsy and other traditionally challenging specimens. Other XNA applications include CRISPR/Cas9 gene-editing event screening and adapter dimer removal for NGS library preparation.

Recent Publications

  • W. Yan, A. Zhang, M. Powell. Genetic Alteration and Mutation Profiling of Circulating Cell-free Tumor DNA (cfDNA) for Diagnosis and Targeted Therapy of Gastrointestinal Stromal Tumors. Chin J Cancer (2016) 35- 68.
  • M. Oktay, E. Adler. L. Hakima, E. Grunblatt, E. Pieri, A. Seymour, S. Khader, A. Cajigas, M. Suhrland, S. Goswami. The Application of Molecular Diagnostics to Stained Cytology Smears. The Journal of Molecular Diagnostics (May 2016) 18 (3): 407–415.
  • M. Myers, M. Banda, KL. McKim, Y. Wang, MJ. Powell, BL. Parsons. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas. Neoplasia. (Apr 2016) 18(4):253-63.
  • H. Luo, H. Du, K. Maurer, JL. Belinson, G. Wang, Z. Liu, L. Zhang, Y. Zhou, C. Wang, J. Tang, Z. Qu, R. Wu. An Evaluation of the Cobas4800 HPV Test on Cervico-Vaginal Specimens in Liquid versus Solid Transport Media. PLoS One. (Feb 2016) 1;11(2):e0148168.
« Show less

DiaCarta, Inc. has not listed any services.

OptiSeq Sequencing
Price on request

OptiSeqTM NGS platform is a game changer that leverages the power of xeno nucleic acid (XNA) technology to detect genetic mutations with ultra-sensitivity and accuracy in liquid biopsy and other challenging samples without deep sequencing. 500X OptiSeqTM reads (with XNA) are equivalent to 50,000X reads without XNA. The platform... Show more »

OptiSeqTM NGS platform is a game changer that leverages the power of xeno nucleic acid (XNA) technology to detect genetic mutations with ultra-sensitivity and accuracy in liquid biopsy and other challenging samples without deep sequencing. 500X OptiSeqTM reads (with XNA) are equivalent to 50,000X reads without XNA. The platform provides a complete sample-to-insight solution. We offer the following panels and more: Pan-cancer, breast, lung, prostate, colon and prostate.

« Show less
Cancer
Next Generation Sequencing (NGS)
Price on request

End-to-end solutions consist of i) sample/library preparation, ii) NGS sequencing, iii) bioinformatics analysis, iv) reporting. NGS applications include whole genome sequencing, exome sequencing, mRNA sequencing, small RNA (miRNA, shRNA) sequencing, ChIP sequencing, amplicon sequencing, 16S metagenomics and disease panel... Show more »

End-to-end solutions consist of i) sample/library preparation, ii) NGS sequencing, iii) bioinformatics analysis, iv) reporting. NGS applications include whole genome sequencing, exome sequencing, mRNA sequencing, small RNA (miRNA, shRNA) sequencing, ChIP sequencing, amplicon sequencing, 16S metagenomics and disease panel sequencing. In addition to nucleic acids from cell lines, tissues and FFPE samples, we are specialized to sequence and analyze DNA/RNA from liquid biopsy samples.

« Show less
CAR-T Cell Therapy Development
Price on request

End-to-end capabilities that include genomic profiling, cytokine assay development and comprehensive CAR-T services. For example, the QClamp® XNA-PCR platform enables the screening of human antibody libraries and detection of rare actionable mutations in oncogenes such as NRAS and EGFR VIII as well as CD19-specific chimeric... Show more »

End-to-end capabilities that include genomic profiling, cytokine assay development and comprehensive CAR-T services. For example, the QClamp® XNA-PCR platform enables the screening of human antibody libraries and detection of rare actionable mutations in oncogenes such as NRAS and EGFR VIII as well as CD19-specific chimeric antigen receptor. The platform also consists of single chain variable fragment (scFV) design, lentivirus and CAR-T cell manufacturing in GMP facility with ISO 13485 certification, CAR expression validation, cytokine induction and real-time cytotoxicity assay and genomic profiling in GLP and CLIA lab settings.

« Show less
Biomarker Analysis
Price on request

Services are performed in our CLIA-certified lab. Clinical testing of liquid biopsy, FFPE tissue and other traditionally challenging samples for biomarker analysis on genomic analysis platforms. e.g. Ultra-sensitive QClamp® qPCR-based assay to detect BRAF V600E mutant with < 0.1% allelic frequency; QFusionTM qPCR-based assay... Show more »

Services are performed in our CLIA-certified lab. Clinical testing of liquid biopsy, FFPE tissue and other traditionally challenging samples for biomarker analysis on genomic analysis platforms. e.g. Ultra-sensitive QClamp® qPCR-based assay to detect BRAF V600E mutant with < 0.1% allelic frequency; QFusionTM qPCR-based assay to detect EML4-ALK and KIF5B-ALK fusion gene variants with 1% allelic frequency; FISH assay for EML4-ALK fusion gene detection.

« Show less
Companion Diagnostic Development
Price on request

Our CDx solutions are designed to accelerate cancer drug development and approval with services including i) design and acquisition of reagents; ii) development of research use only (RUO) assay; iii) analytical verification and validation, iv) manufacturing and validation of lab-developed test (LDT) assay, v) IVD development. All... Show more »

Our CDx solutions are designed to accelerate cancer drug development and approval with services including i) design and acquisition of reagents; ii) development of research use only (RUO) assay; iii) analytical verification and validation, iv) manufacturing and validation of lab-developed test (LDT) assay, v) IVD development. All services are performed in our CLIA- and ISO 13485-certified facility. Our clinical services labs are located in United States and China.

« Show less
CRISPR Screening
Price on request

A convenient and rapid method for i) mutant screening after CRISPR/Cas9 edited genomic DNA sequences; ii) screening of large numbers of edited cell populations to determine the frequency of edits; iii) detection of both HDR and NHEJ gene edits. The method involves a simple real-time PCR assay that uses primers to amplify a region... Show more »

A convenient and rapid method for i) mutant screening after CRISPR/Cas9 edited genomic DNA sequences; ii) screening of large numbers of edited cell populations to determine the frequency of edits; iii) detection of both HDR and NHEJ gene edits. The method involves a simple real-time PCR assay that uses primers to amplify a region 80-100 bp that span the edited locus. No laborious gel electrophoresis required, and the method works when T7 endo and Surveyor methods fail.

« Show less
DNA Sequencing
Price on request
Request a quote for more information about this service.
Protein Services
Price on request
Request a quote for more information about this service.
Biology
Price on request
Request a quote for more information about this service.
In vitro Genetic Screening
Price on request
Request a quote for more information about this service.
Genetic Engineering
Price on request
Request a quote for more information about this service.
DNA
Price on request
Request a quote for more information about this service.
Pharmacology & Toxicology
Price on request
Request a quote for more information about this service.
Bioanalysis
Price on request
Request a quote for more information about this service.
Antibody Services
Price on request
Request a quote for more information about this service.
Biomarkers
Price on request
Request a quote for more information about this service.
Biochemistry & Molecular Biology
Price on request
Request a quote for more information about this service.
Nucleic Acid Services
Price on request
Request a quote for more information about this service.
Medical Devices & Diagnostics
Price on request
Request a quote for more information about this service.
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

DiaCarta, Inc. has not received any ratings.

Be the first to endorse DiaCarta, Inc.

Endorse this lab